National Institutes of Health: Leiomyoma trials

The registry lists 13 Leiomyoma studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 2 5No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal CancerRecruitingNCT00050752
• Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum ToxinCompletedNCT00971620Phase 2Results posted
• Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914CompletedNCT00290251Phase 2Results posted
• COVID-19 Experiences in the SELF CohortCompletedNCT05369611
• Establishment of Fibroid Tissue BankTerminatedNCT00710346
• Postpartum Uterine RegressionCompletedNCT00341848
• Fibroid Growth StudyCompletedNCT00340288
• Risk Factors for Uterine Fibroids: A Case Control StudyCompletedNCT00339547
• Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)CompletedNCT00332033Phase 2
• Self-Hypnotic Relaxation Therapy During Invasive ProceduresCompletedNCT00087841Phase 2
• Women's Use of Alternative Medicine: A Multiethnic StudyCompletedNCT00067249
• Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor AntagonistCompletedNCT00044876Phase 2
• Evaluation of Women With Endocrine and Reproductive-Related ConditionsTerminatedNCT00001850